Under construction – not a live service
Sign in
Not yet taking people in EgyptPhase 1/2

Atorvastatin to Limit Heart Damage From Anthracycline Chemotherapy

Tests atorvastatin to reduce heart damage in adults receiving anthracycline chemotherapy for blood cancers.

Key facts

Who runs it
Assiut University
Where
Asyut, EgyptSee the site
Trial code
Registry title
Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
46 people, planned
Started
Nov 2024
Expected to end
Sept 2029
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Atrovastain
Record updated
12 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with acute myeloid leukemia or non-Hodgkin lymphoma who are starting anthracycline chemotherapy and have good heart function. It tests atorvastatin to protect the heart.

Age
Older than 18 years
Sex
All sexes
Disease stage
Acute myeloid leukemia treated with the 3,7 regimen, or non-Hodgkin lymphoma treated with the CHOP regimen.
Biomarker or test result
Heart pumping function (EF) of 60% or more.

Main reasons for not taking part

  • Heart dysfunction with EF below 60%
  • Other blood cancers
  • Pregnant or breastfeeding women
  • People who refuse to take part in the research

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Age >18 years Patient with hematologic malignany ( Acute myeloid leukemia on 3,7 regimen or non-Hodkin Lymphoma on CHOP regimen) Cardiac function with EF ≥60%

Who cannot take part

  • Cardiac dysfunction with EF < 60% Other hematologic malignancies Pregnant women and breastfeeding Patients refuse participate in research

Where in Egypt

  • Assiut UniversityAsyut, EgyptContact: Assiut universityNo longer taking part

About the trial

What the trial wants to find out

The research proposal focuses on evaluating the efficacy of atorvastatin in reducing cardiotoxicity caused by anthracycline chemotherapy in patients with hematologic malignancies, specifically acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL). The study will be conducted at Assiut University Hospitals and will include patients aged 18 or older receiving anthracycline-based treatments (3+7 regimen for AML and CHOP regimen for NHL).

Read full original descriptionShow less

The background highlights that anthracyclines, a class of chemotherapeutic agents, can cause serious side effects, particularly cardiotoxicity. The research aims to investigate whether atorvastatin, a statin used to lower cholesterol, can mitigate this risk by improving cardiac function in patients undergoing chemotherapy.

The study will be a randomized controlled trial with a sample size of 46 participants. It will assess left ventricular ejection fraction (LVEF) as the primary outcome to determine the effect of atorvastatin on reducing cardiotoxicity. Secondary outcomes include identifying high-risk patients and further understanding the impact of atorvastatin.

The study also adheres to ethical guidelines, ensuring patient consent and confidentiality. Data analysis will be performed using IBM SPSS, and results will be disseminated in scientific journals, with support from Assiut Medical School's Grants Office if funding is approved.

The 2 groups in the trial

  • Non Atrovastatin groupNo study treatment, for comparison

    control group of the same condition they will not tkae atrovastatin

  • Atrovastatin groupTreatment being tested

    patients will receive atorvaststin 40mg/daily , started before anthracyclin treatment and continued 12 months

    Treatment: Atrovastain

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Using of Atorvastatin for Anthracyclin _ Associated Cardiotoxicity in Hemetological Malignancies Patients.
Plain-language title
Atorvastatin to Limit Heart Damage From Anthracycline ChemotherapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
12 November 2024